CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$51.78
+3.57%Margins
Gross margin
-1079.5%
EBITDA margin
-1826.4%
EBIT margin
-2104.9%
Net margin
-1812.1%
FCF margin
-1506.4%
-27.7%
Return on equity
-17.8%
Return on assets
-21.8%
Return on invested capital
0.01x
Asset turnover
-$374.6M
Cash from operations
$23
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026